Brought to you by:
-
Reflections from VESS: Internal mentoring, external inspiration and really good skiing
Just over a week ago, I was racing my medical school vascular surgery attending, Dr. Adam Doyle, down a Breckenridge run memorably named “The Devil’s Crotch.” We were celebrating fresh powder, the conclusion of an excellent fellows program, and the opportunity to reconnect with old students (for him), and with familiar faculty and friends (for…
-
Study demonstrates textbook outcomes occur less than a quarter of the time after CLTI revascularization
Textbook outcomes remain “very rare” after revascularization for chronic limb-threatening ischemia (CLTI), with the main driver being an enduring inability to attain complete wound healing and to return patients to their preoperative ambulatory status, according to the lead researcher behind a new study looking into a version of the performance outcome metric. Jayer Chung, MD,…
-
Countdown to New Orleans: VAM 2025 set to explore innovation
The 2025 Vascular Annual Meeting (VAM) will take place in New Orleans, Louisiana, from June 4–7, with a particular focus this year on innovation. Key program highlights coming up this year include case-based learning sessions entitled “Optimal Management of the ‘No Option’ CLTI Patient” and “Spinal Cord Ischemia,” as well as interactive courses with topics…
-
BEST-CLI trial spline model analysis breaks new ground in assessing the impact of CKD severity on CLTI outcomes
A new analysis of the BEST-CLI trial has produced the first evidence-based glomerular filtration rate (eGFR) value—30 mL/min/1.73 m2—as the cutoff below which patients with chronic limb-threatening ischemia (CLTI) experience significantly worse outcomes after revascularization regardless of the treatment modality performed. The data were part of a deep dive into the landmark study in an…
-
Deep vein arterialization: Much remains to be learned but use poised to expand in patients with less severe ischemia
These remain early days for transcatheter arterialization of the deep veins (TADV) in the setting of patients with severe chronic limb-threatening ischemia (CLTI), says Daniel Clair, MD, one of the principal investigators in key clinical trials of the procedure, but the learning-curve process promises that “we are going to continue to see slow but not…
-
Boston Scientific, carotid, carotid artery stenosis, Carotid disease, Enroute, ROADSTER, ROADSTER 3, Silk Road Medical, TCAR, VIVA24
ROADSTER 3 provides key evidence that ‘goes beyond registry data’ on TCAR-related stroke rates
Thirty-day results from the ROADSTER 3 study have demonstrated that transcarotid artery revascularization (TCAR) is a safe and effective approach in patients who are deemed to be standard risk for experiencing adverse events related to carotid endarterectomy (CEA). These findings were presented at the 2024 Vascular InterVentional Advances (VIVA) conference (Nov. 3–6) in Las Vegas…
-
Aortic Research Consortium, CSF drains, F-BEVAR, SAVS 2025, Southern Association for Vascular Surgery, spinal cord ischemia
US ARC uncovers ‘dramatic’ decrease in use of prophylactic spinal drains at same time as spinal cord ischemia steeply declines
Despite a “dramatic” decrease in the use of prophylactic cerebrospinal fluid drains (CSFDs) for the prevention of spinal cord ischemia (SCI) in patients undergoing fenestrated and branched endovascular aortic repair (F/BEVAR), the rate of SCI has tracked a similarly dramatic decrease, according to the senior author of a new analysis of U.S. Aortic Research Consortium…
-
Tracci assumes presidency of Southern Vascular
Margaret (Megan) Tracci, MD, has become the first-ever woman president of the Southern Association for Vascular Surgery (SAVS). The University of Virginia professor of surgery assumed the role at the close of the 2025 SAVS annual meeting in St. Thomas, the U.S. Virgin Islands (Jan. 22–25). Tracci took over from Alan Lumsden, MD, medical director…
-
One-year SAVVE trial results are ‘most encouraging data ever produced for a bioprosthetic vein valve’
The one-year data from the SAVVE trial represent the “most encouraging clinical data that have ever been produced for a bioprosthetic deep vein valve” in more than half a century of attempts at developing such a device, according to one leading venous disease specialist. Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, cautiously…
-
CLTI, EFEMORAL I, Efemoral Medical, Efemoral Vascular scaffold system, Midwestern Vascular Surgical Society, MVSS 2024
Novel sirolimus-eluting scaffold system demonstrates ‘potential to address Achilles’ heel’ of currently available endovascular treatment options
Ongoing studies of the Efemoral vascular scaffold system (EVSS)—previously described as a potential new paradigm in the treatment of long occlusive lesions—show that the device continues to show promise, according to investigators. The latest animal study assessed the subacute response to implantation of the novel, sirolimus-eluting bioresorbable system in 10 arteries of five female mini-swine,…